Johnson & Johnson (NYSE: JNJ) today announced the publication of data detailing the differentiated molecular properties of nipocalimab, an investigational neonatal Fc receptor (FcRn) blocker, in ...

A nationwide red blood cell alloantibody exchange could reduce mortality among alloimmunized individuals with sickle cell disease, according to study results presented at ASH Annual Meeting and ...

NEW ORLEANS — Save lives, save money. What's not to love? That's the claim made for a proposed national exchange or registry of data on alloantibodies. These are antibodies that develop in ...

It is commonly accepted that B-cell activation and alloantibody production requires signals provided by CD4 + Th cells, activated through the indirect allorecognition pathway.

Such autoantibodies have the potential to amplify microcirculation injury caused by alloantibody in antibody-mediated transplant rejection. Nature Reviews Nephrology ...

Nipocalimab resulted in more live births at 32 weeks’ gestation or later without fetal anemia or intrauterine transfusion for pregnancies at risk for early-onset severe hemolytic disease of the ...

Nipocalimab is an investigational neonatal Fc receptor (FcRn) blocker that aims to "inhibit alloantibody transfer to the fetus and to lower maternal IgG alloantibody titers," they wrote.